Hyper‐CVAD and Modified CALGB‐10403 Regimens in Adult Patients With Philadelphia‐Negative Acute Lymphoblastic Leukemia: A Comparative Study

• DOI: 10.1111/ejh.14381
• Publication Date: 2025-01-08T07:49:42Z
• Authors: Jessica Zalapa‐Soto; Fausto Alfredo Ri...; Lyam Carlo Chacón...; Analy Mora‐Cañas; Mario Meza‐Meza; Juan Rangel‐Patiño; Roberta Demicheli...
• Keywords: Regimen; Clinical endpoint; Acute lymphocytic leukemia

ABSTRACT Objective Acute lymphoblastic leukemia (ALL) has a higher incidence in Latin America, with adult patients experiencing worse long‐term outcomes despite high complete remission (CR) rates. When treated regimens, 3‐year overall survival (OS) is approximately 20%. However, adopting pediatric‐inspired regimens (PIRs) shown improved outcomes. Methods We performed comparative analysis of Hispanic newly diagnosed Ph‐negative ALL, either PIR, modified CALGB 10403 (mCALGB), or the regimen Hyper‐CVAD between January 2015 and May 2023. The primary endpoint was OS among secondary endpoints relapse‐free (RFS). Results included 100 patients, 35 were 65 mCALGB. Median age 26 years (range, 20.2–38). median 54.2 months (95% CI 28.3–80.1), non‐reached mCALGB group NR‐NR) versus 22.4 13.7–31) for Hyper‐CVAD. 64.9% 34.9%, p = 0.034. Treatment independently associated (HR 0.29, 95% 0.13–0.66, 0.003) RFS 0.14–0.59, < 0.001). Conclusions benefits regarding when compared to